China Reforms Lead To Monopoly Drug Buyer, Threatening MNC Profits
This article was originally published in PharmAsia News
Executive Summary
For global pharmaceutical companies, China's bubble may be about to burst along with high profits as the country's reform efforts in the health system begin to bite in the next few years.